The Unbelievably Innovative Dr. David Samadi

Dr. David Samadi is a celebrity doctor, who specializes in the diagnosis and treatment of urologic diseases, such as prostate cancer, kidney and bladder cancer. He is well known for his technique in advanced minimally invasive treatments for prostate cancer. His experiences as a young boy has shaped him into one remarkable surgeon he is today.He grew up in Iran, but at the tender age of 15 he was forced to leave his birth place and family because of the Iranian revolution. He eventually made way to New York where he completed high school in Roslyn, NY. He earned a degree in biochemistry on a full scholarship at the State University of New York at Stony Brook School of Medicine. He completed his post-graduate training at Montefiore Medical Center and in urology at Albert Einstein School of Medicine and Montefiore Medical Center.Dr. David Samadi is the only surgeon to perform the SMART surgery technique using the da Vinci robotic system.

Using the Da Vinci system the incisions are much smaller than conventional prostate surgery. The delicate prostate nerve will be saved by less damage, and a faster recovery. Dr. David Samadi is highly active on social media to promote is weekly TV show SamadiTV. SamadiTV is a weekly live-stream show that premiers every Sunday at 12:30 PM EST. It features relevant health topics providing the public with answers and advice on good health. With his many awards and wide recognition, he lives up to the name given by New York Magazine as the Best Doctor year after year. He has also been honored by the following: Vitals Patients’ Choice Award 2008-2014, Castle Connolly Top Doctors – The Top 1,251 Physicians, New York Magazine 2013-2014, New York Sup

er Doctors 2014, America’s Top Doctors for Cancer 2009-2014, Best Doctors New York Magazine 2009-2012, 2015. America’s Top Doctors 2008-2013, Most Compassionate Doctor 2010-201.He believes that Mitt Romney has a very high recovery rate and a chance to avoid any relapse of the cancer. He states that Romney chose to have surgery and believes this can be the best choice for certain patients. He is also certain that a diagnosis like this one has a very good lasting outlook.During his interview with Ideamensch, Dr. David Samadi unfolds a look at a day in his life. He wakes up early at around 4:30 am and reaches his office by 6:00 am. He remains on he feet throughout the rest of the day, performing numerous surgeries. The Dr. also reveals that he has a photographic memory, and that he sketches out his ideas that appear to him through the day.Dr. David Samadi is not only a remarkable and respected surgeon, he is an extraordinary human who continues to save lives, and educate the public. He has truly lived up to his title as the BEST DOCTOR.

Listen and interact with Dr. David Samadi on his Weekly Medical Show

They say information is power. This is very true but the source of information is also very crucial. In a world dominated by divisive politics sometimes it can be hard to find reliable information sources. Besides, almost everyone has access to the internet and they can relay information which is not accurate. But when it comes to serious information such as those that deal with healthcare, you definitely need an expert. That is probably why “Sunday Housecall with Dr. Samadi” show is the probably the best source of reliable information.

The “Sunday Housecall with Dr. David Samadi” program went live on Sempter 2017 and has been well received by a majority of people. The program is broadcasted every Sunday from 12.30 in the afternoon. It is a very interactive show where Dr. Samadi covers different topics related to technological advancements in the medical field and how they are affecting patients. Viewers also have a chance to call in or send emails to ask questions while the show is ongoing. In addition, the show is aired on different platforms including; YouTube, Facebook as well as Dr. David Samadi’s professional website.

At this juncture, you might still be wondering who Dr. David Samadi really is and why all the fuss about him. Dr. David Samadi came into the limelight through Fox news where he used to be a guest commentator by virtue of being a celebrity doctor. He gained popularity on major Television and radio talk shows because of his vast experience and experience in the medical field. Besides that, Dr. David Samadi is an established doctor with a vibrant medical practice in New York. He currently works at the Lennox Hill hospital where he focuses on fighting cancer through robotic surgery, and David Samadi on Facebook.

Dr. David Samadi’s credentials speak for themselves. He went at Roselyn, New York for his high school and attended Stony Brook University where he got his biochemistry degree. He also attended Stony Brook School of medicine where he earned his M.D. He later went to Montefiore Medical Center and Einstein College of medicine where he finished his training in Urology and proctology respectively. He has also gone to France where he studied robotic surgery an area where he has a lot of passion with.

The “Sunday Housecall with Dr. Hamadi” is not a one-man show. He often invites guest speakers from different sectors of the healthcare system to address issues of concern. It is generally an interactive platform for medical discourse, and http://insider.foxnews.com/tag/dr-david-samadi.

The Purpose of Cancer Treatment Centers of America

Cancer care specialists are working hard to slow and/or stop cancer progression. Every new medical advance gets them one step closer to the goal. Cancer Treatment Centers of America has unveiled a thrilling data and informational collection platform accessed through the hospital computer system. This is expected to save cancer staff massive amounts of valuable time. This is also designed to decrease any chances of choosing a wrong cancer medication, or missing a new cancer treatment suitable for one of their patients. More efficiency and faster information access will aid all CTCA staff eventually.

This technological advancement is just one of the ever changing face of a CTCA expected cancer care practice. This organization likes to remain on the cutting edge of new discoveries able to help their many cancer patients. This is why research is so encouraged by this healthcare institution. For now, Cancer Treatment Centers of America will continue to deliver highly specialized cancer care to their needy patients. Everyone on a patient’s designated team works hard to ensure the best outcome for every patient that comes through the doors. When one patient leaves, another arrives swiftly. Hopefully there could be a slow down in cancer diagnoses if cancer care keeps getting better.

Most patients arrive scared and unsure of their fragile futures. The holistic framework that CTCA operates on empowers patients soon after arrival. This hope is what drives many patients each day that they fight their long hard battles. The patients will say it is worth it when they are able to go home. Their loving families are grateful for more time together. Cancer Treatment Centers of America instills a sense of purpose in every cancer care staff member’s roles. Every action is a part of a personalized care plan. CTCA is many patient’s hope.

Visit More : http://www.myctca.com

Benefits of the Popular Seattle Genetics Company

Seattle Genetics is one of the largest biotechnology companies in the industry and continues to grow to be bigger and better each and every day. Because of its size, many people have been working for Seattle Genetics and consider it a wonderful career. Not only is this company great to work for, but they also make leaps and bounds when it comes to getting biotechnology better understood and explained to the public and the medical industry in particular.

Seattle Genetics (SGEN) Clay B. Siegall on Q2 2016 Results – Earnings Call Transcript
Clay Siegall is the CEO of the company and has worked with them since the beginning. He is both the president and CEO and takes it into his own hands to grow the company to what you see today. There are a lot of reasons Clay Siegall makes the company what it is, but his education and experience are two of the most important things when it comes to his work with the company itself. There are many reasons for why you might want to learn more about Clay Siegall, so you can find him on a wide range of different social media accounts out there for your own benefit.

Seattle Genetics is a great company that continues to take strides to benefit those making use of their services. Between their work in biotechnology to their work with the public, it is no wonder this particular company is one of the most popular you could find out there. Seattle Genetics can be found online and is a great option for you. There are lots of ways to find them on the Internet, so you can find them on social media and make use of their services to ensure that this is something that is beneficial to you. For a lot of people, making use of the Seattle Genetics company as well as its CEO and owner Clay Siegall, there are lots of reasons to consider using the company for what it is able to offer to the public. Make sure that you find out as much as possible about Seattle Genetics if this is a company you want to learn more about.

https://claysiegallblog.wordpress.com/

http://claysiegall.tumblr.com/

Seattle Genetics: Experience, Achievements, Successful Oncology

Seattle Genetics is a biotechnology company which focuses on the development and commercialization of innovative therapies, for cancer treatment, based on empowered monoclonal antibodies. It is the industry leader in ADCs, or antibody-drug conjugates, a technology created to focus cell-killing agents directly to cancer cells, by improving monoclonal antibodies’ targeting abilities.

The company was co-founded, in 1998, by its current Chairman, President & CEO, Clay Siegall, a Ph.D with broad pharmaceutical industry experience; and done so with a passion for helping patients, a foundation of innovative science, rigorous research and drug development practices. The focus is to, through antibody-drug conjugates, enhance antitumor activity while sparing non-targeted cells, to reduce as many of the toxic effects of traditional chemotherapy as possible.

Under the stewardship of Dr. Siegall, Seattle Genetics has formed part of multiple strategic licenses for its antibody-drug conjugates technology that have procured more than $300 million so far. He has also led the company’s capital-raising activities, which have led to more than $675 million, through public and private financing.

Clay Siegall is a graduate of the University of Maryland where he earned a Bachelor’s Degree in Zoology; and The George Washington University where he earned a Doctorate in Genetics. Since then he has worked for the Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, National Institutes of Health.

Since the foundation of Seattle Genetics, he has been the director and board member of Alder Biopharmaceuticals Inc., a biopharmaceutical company which discovers, develops and commercializes therapeutic antibodies; Mirna Therapeutics, Inc., a company which develops microRNA-based oncology therapeutics; and Ultragenyx Pharmaceutical, a company which, with a focus on serious and debilitating genetic diseases, develops products to treat rare and ultra-rare illnesses.

Seattle Genetics’ successful oncology advances have lead to the development of Brentuximab vedotin, or ADCETRIS, as per its trade name. It is the company’s flagship product and an ADC which targets the CD30 protein; this protein is expressed in classical Hodgkin lymphoma, a type of lymphoma, in which cancer develops from a white blood cells called lymphocytes; as well as in systemic anaplastic large cell lymphoma, a type of non-Hodgkin lymphoma which involves abnormal T-cells.

https://www.linkedin.com/in/claysiegall

http://www.bloomberg.com/research/stocks/people/person.asp?personId=607509&privcapId=34145http://www.bloomberg.com/research/stocks/people/person.asp?personId=607509&privcapId=34145

http://www.bloomberg.com/research/stocks/people/person.asp?personId=607509&privcapId=34145